The overall goal of the Clinical Core is to generate data and biospecimens required to support high quality, cutting edge, externally-funded clinical and clinical-pathologic studies that focus on the full spectrum of cognition from normal aging to mild cognitive impairment (MCI) to the earliest stages of dementia among older African Americans. Historically, progress in Alzheimer's disease (AD) research has been most striking among members of the U.S. non-Hispanic white population. However, because of the expected increase in the growth of the older African American population, because African Americans may be at greater risk of AD than whites, and the burden of AD and mixed dementias is projected to increase dramatically for this population, the Rush Clinical Core will focus on enrolling and following African Americans longitudinally to accomplish the following Specific Aims: 1) Continue to recruit and enroll African Americans without dementia who agree to annual, detailed clinical evaluations and collection of ante-mortem biologic specimens;2) Continue to conduct uniform structured baseline and annual follow-up evaluations, including neurological examination and neuropsychological performance testing, of community-dwelling Clincal Core participants, apply uniform diagnostic criteria for incident AD, MCI, and mixed dementias as specified in the UDS, and supplement UDS data collection with an extended battery of tests to increase compatibility with the Religious Orders Studies Core;3) Integrate innovative and culturally tailored educational programs into the clinical evaluation to increase awareness of the importance of brain autopsy in African Americans and to facilitate a high autopsy rate with a short post-mortem interval;and continue to harvest and preserve the brain tissue in a fashion that retains maximum flexibility to support a diverse array of studies;and 4) Increase capacity to conduct externally funded clinical, neuropsychological, and clinical-pathological research studies, including studies that incorporate contemporary biochemical and molecular techniques, by contributing data to NACC and providing an environment and resources to facilitate entry of subjects, clinical data, and post-mortem tissue into research projects at Rush and within the AD research community at large.

Public Health Relevance

The Rush Clinical Core will generate data and biospecimens to support high quality, cutting edge clinical and clinical-pathologic studies that focus on the full spectrum of cognition in older African Americans, one of the fastest growing populations in the U.S. Knowledge gained through studies supported by the Core will advance our understanding of the clinical and neuropathoiogic transitions from normal cognition to dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010161-22
Application #
8381371
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
22
Fiscal Year
2012
Total Cost
$371,454
Indirect Cost
$128,674
Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Bernier, Patrick J; Gourdeau, Christian; Carmichael, Pierre-Hugues et al. (2017) Validation and diagnostic accuracy of predictive curves for age-associated longitudinal cognitive decline in older adults. CMAJ 189:E1472-E1480
Brenowitz, Willa D; Keene, C Dirk; Hawes, Stephen E et al. (2017) Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging 53:83-92
Buchman, Noa M; Leurgans, Sue E; Shah, Raj J et al. (2017) Urinary Incontinence, Incident Parkinsonism, and Parkinson's Disease Pathology in Older Adults. J Gerontol A Biol Sci Med Sci 72:1295-1301
Sposato, Luciano A; Ruíz Vargas, Estefanía; Riccio, Patricia M et al. (2017) Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. Alzheimers Dement 13:770-777
Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148
Klaver, Andrea C; Coffey, Mary P; Bennett, David A et al. (2017) Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study. Transl Neurodegener 6:32
Yu, Lei; Dawe, Robert J; Buchman, Aron S et al. (2017) Ex vivo MRI transverse relaxation in community based older persons with and without Alzheimer's dementia. Behav Brain Res 322:233-240
Ahmad, Faraz; Singh, Kunal; Das, Debajyoti et al. (2017) Reactive Oxygen Species-Mediated Loss of Synaptic Akt1 Signaling Leads to Deficient Activity-Dependent Protein Translation Early in Alzheimer's Disease. Antioxid Redox Signal 27:1269-1280
Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528
Burke, Shanna L; O'Driscoll, Janice; Alcide, Amary et al. (2017) Moderating risk of Alzheimer's disease through the use of anxiolytic agents. Int J Geriatr Psychiatry 32:1312-1321

Showing the most recent 10 out of 689 publications